We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Neem Tree Extract Halts Pancreatic Cancer Growth in Mouse Models

By LabMedica International staff writers
Posted on 21 Feb 2016
Nimbolide, a compound extracted from the leaves of the neem tree (Azadirachta indica), was shown in culture and mouse models to have potential as a chemotherapeutic agent for the treatment of pancreatic cancer.

The mortality and morbidity rates of pancreatic cancer are high (94% of patients die within five years of diagnosis) due to its extremely invasive and metastatic nature. More...
Absence of symptoms, late diagnosis, chemo-resistance, and lack of effective treatment warrant the development of new chemotherapeutic agents.

Compounds from medicinal plants have demonstrated therapeutic benefits in various human cancers. Among them are nimbolide, a triterpenoid present in the edible parts of the neem tree, which displays a variety of biological activities including antimalarial and anticancer properties. Recently it was shown that nimbolide sensitized colon cancer cells to apoptosis through three distinct mechanisms: production of reactive oxygen species, downregulation of cell survival proteins, and upregulation of pro-apoptotic proteins. Products made from neem trees have been used in India for over two millennia for their medicinal properties. Neem products are believed to be anthelminthic, antifungal, antidiabetic, antibacterial, antiviral, contraceptive, and sedative. Neem oil is used for healthy hair, to improve liver function, detoxify the blood, and balance blood sugar levels. Neem leaves have also been used to treat skin diseases such as eczema and psoriasis.

Investigator at the Texas Tech University Health Sciences Center (El Paso, USA) evaluated the potential of nimbolide for the treatment of pancreatic cancer.

They reported in the January 25, 2016, online edition of the journal Scientific Reports that nimbolide induced excessive generation of reactive oxygen species (ROS), thereby regulating both apoptosis and autophagy in pancreatic cancer cells. Experiments with the autophagy inhibitors 3-methyladenine and chloroquine diphosphate salt and the apoptosis inhibitor z-VAD-fmk demonstrated that nimbolide-mediated ROS generation inhibited proliferation and metastasis via mitochondrial-mediated apoptotic cell death but not via autophagy.

Experiments conducted on mice demonstrated that nimbolide was effective in inhibiting pancreatic cancer growth and metastasis without harming normal, healthy cells.

"Nimbolide seems to attack pancreatic cancer from all angles," said senior author Dr. Rajkumar Lakshmanaswamy, associate professor of biomedical sciences at the Texas Tech University Health Sciences Center. "The promise nimbolide has shown is amazing, and the specificity of the treatment towards cancer cells over normal cells is very intriguing."

Related Links:

Texas Tech University Health Sciences Center



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.